Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary Syndrome

NCT02483299 on ClinicalTrials.gov · last registry update 2015-06-26

Finished April 2015, after enrolling 40 people. Primary outcome, as filed: Change in body weight. liraglutide is approved in the US, but not for pcos — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: University Medical Centre Ljubljana
Sponsor type: Other
Enrollment: 40
Started: 2014-01
Primary completion: 2015-04 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in body weight

Conditions studied

PCOS · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.